Abstract
Endometrial cancer is the most frequent gynecological malignancy in developed world. Cancer stem cells (CSC) are recognized as a small proportion of cells among the tumor cell population that are capable of self-renewal, aberrant differentiation, and escape homeostasis. This review aims to systematize the existing evidence of CSC of endometrial cancer and its clinical translation. In endometrial cancer, the cancer stem cell hypothesis has been studied in vitro using the isolation of colony forming units, side population with dye efflux capacity, and tumorospheres. The stem cell markers for endometrial cancer do not have uniform characteristics, albeit CD133 and aldehyde dehydrogenase (ALDH) were being associated with CSC phenotype. The application of endometrial CSC on xenograft models proves the tumorigenic capacity of this small group of cells. The metastatic process has been explained due to epithelial-mesenchymal transition (EMT) in which CSC seems to have a critical role. The chemoresistance is characteristic of CSC that in endometrial cancer has been shown in CSC phenotype and associated with CSC markers. The most ambitious potential for CSC is the development of targeted therapies. Its application on endometrial cancer is still poor, being a future perspective for research.
Similar content being viewed by others
References
Colombo, N., Preti, E., Landoni, F., Carinelli, S., Colombo, a, Marini, C., Sessa, C. (2011). Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology/ ESMO, 22 Suppl 6(Supplement 6), vi35–9. doi:10.1093/annonc/mdr374
Burke, W. M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A. B., & Abu Shahin, F. (2014). Endometrial cancer: a review and current management strategies: part I. Gynecologic Oncology, 134(2), 385–392. doi:10.1016/j.ygyno.2014.05.018.
Fambrini, M., Sorbi, F., Sisti, G., Cioni, R., Turrini, I., Taddei, G., & Guaschino, S. (2014). Endometrial carcinoma in high-risk populations: is it time to consider a screening policy? Cytopathology, 25(2), 71–77. doi:10.1111/cyt.12131.
Weiderpass, E., Antoine, J., Bray, F. I., Oh, J. K., & Arbyn, M. (2014). Trends in corpus uteri cancer mortality in member states of the European Union. European Journal of Cancer, 50(9), 1675–1684. doi:10.1016/j.ejca.2014.02.020.
Murali, R., Soslow, R. A., & Weigelt, B. (2014). Classification of endometrial carcinoma: more than two types. The Lancet Oncology, 15(7), e268–78. doi:10.1016/S1470-2045(13)70591-6.
Pike, M. C., Peters, R. K., Cozen, W., Probst-Hensch, N. M., Wan, P. C., Mack, T. M., & Felix, J. C. (1997). Estrogen-progestin replacement therapy and endometrial cancer. Journal of the National Cancer Institute, 89(15), 1110–1116. doi:10.1093/jnci/89.15.1110.
Soliman, P. T., Wu, D., Tortolero-Luna, G., Schmeler, K. M., Slomovitz, B. M., Bray, M. S., & Lu, K. H. (2006). Association between adiponectin, insulin resistance, and endometrial cancer. Cancer, 106(11), 2376–2381. doi:10.1002/cncr.21866.
Fisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., & Cronin, W. M. (1994). Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. Journal of the National Cancer Institute, 86(7), 527–537. doi:10.1093/jnci/86.7.527.
Zhou, B., Yang, L., Sun, Q., Cong, R., Gu, H., Tang, N., & Wang, B. (2008). Cigarette smoking and the risk of endometrial cancer: a meta-analysis. The American journal of medicine, 121(6), 501–508.e3. doi:10.1016/j.amjmed.2008.01.044.
Timmermans, A., Opmeer, B. C., Khan, K. S., Bachmann, L. M., Epstein, E., Clark, T. J., & Mol, B. W. J. (2010). Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstetrics and Gynecology, 116(1), 160–167. doi:10.1097/AOG.0b013e3181e3e7e8.
Bokhman, J. V. (1983). Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology, 15(1), 10–17.
Chiang, S., & Soslow, R. A. (2014). Updates in diagnostic immunohistochemistry in endometrial carcinoma. Seminars in Diagnostic Pathology, 31(3), 205–215. doi:10.1053/j.semdp.2014.03.002.
Simpkins, S. B., Peiffer-Schneider, S., Mutch, D. G., Gersell, D., & Goodfellow, P. J. (1998). PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. Gynecologic Oncology, 71(3), 391–395. doi:10.1006/gyno.1998.5208.
Darvishian, F., Hummer, A. J., Thaler, H. T., Bhargava, R., Linkov, I., Asher, M., & Soslow, R. A. (2004). Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. The American Journal of Surgical Pathology, 28(12), 1568–1578.
Llauradó, M., Ruiz, A., Majem, B., Ertekin, T., Colás, E., Pedrola, N., & Reventós, J. (2012). Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. Molecular and Cellular Endocrinology, 358(2), 244–255. doi:10.1016/j.mce.2011.10.003.
Zannoni, G. F., Vellone, V. G., Arena, V., Prisco, M. G., Scambia, G., Carbone, A., & Gallo, D. (2010). Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Archiv, 457(1), 27–34. doi:10.1007/s00428-010-0939-z.
Yamamoto, S., Tsuda, H., Aida, S., Shimazaki, H., Tamai, S., & Matsubara, O. (2007). Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Human Pathology, 38(7), 1074–1080. doi:10.1016/j.humpath.2006.12.018.
Moreno-Bueno, G., Hardisson, D., Sarrió, D., Sánchez, C., Cassia, R., Prat, J., & Palacios, J. (2003). Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. The Journal of Pathology, 199(4), 471–478. doi:10.1002/path.1310.
Schlosshauer, P. W., Ellenson, L. H., & Soslow, R. A. (2002). Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Modern Pathology, 15(10), 1032–1037. doi:10.1097/01.MP.0000028573.34289.04.
Cheung, L. W. T., Hennessy, B. T., Li, J., Yu, S., Myers, A. P., Djordjevic, B., & Mills, G. B. (2011). High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discovery, 1(2), 170–185. doi:10.1158/2159-8290.CD-11-0039.
McConechy, M. K., Ding, J., Cheang, M. C. U., Wiegand, K. C., Senz, J., Tone, A. A., & Huntsman, D. G. (2012). Use of mutation profiles to refine the classification of endometrial carcinomas. Journal of Pathology. doi:10.1002/path.4056.
Tashiro, H., Isacson, C., Levine, R., Kurman, R. J., Cho, K. R., & Hedrick, L. (1997). p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. The American Journal of Pathology, 150(1), 177–185.
Jia, L., Liu, Y., Yi, X., Miron, A., Crum, C. P., Kong, B., & Zheng, W. (2008). Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clinical Cancer Research, 14(8), 2263–2269. doi:10.1158/1078-0432.CCR-07-4837.
Network, C. G. A. R., Institute, G. sequencing centres: B., Getz, G., Gabriel, S. B., Cibulskis, K., Lander, E., … Committee, W. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497(7447), 67–73. doi:10.1038/nature12113
Gargett, C. E., & Masuda, H. (2010). Adult stem cells in the endometrium. Molecular Human Reproduction, 16(11), 818–834. doi:10.1093/molehr/gaq061.
Gargett, C. E., Chan, R. W. S., & Schwab, K. E. (2008). Hormone and growth factor signaling in endometrial renewal: role of stem/progenitor cells. Molecular and Cellular Endocrinology, 288(1-2), 22–29. doi:10.1016/j.mce.2008.02.026.
Salamonsen, L. A. (2003). Tissue injury and repair in the female human reproductive tract. Reproduction, 125(3), 301–311. doi:10.1530/rep.0.1250301.
Giudice, L. C. (2003). Elucidating endometrial function in the post-genomic era. Human Reproduction Update, 9(3), 223–235. doi:10.1093/humupd/dmg019.
Chan, R. W. S., Schwab, K. E., & Gargett, C. E. (2004). Clonogenicity of human endometrial epithelial and stromal cells. Biology of Reproduction, 70(6), 1738–1750. doi:10.1095/biolreprod.103.024109.
Kato, K., Yoshimoto, M., Kato, K., Adachi, S., Yamayoshi, A., Arima, T., & Wake, N. (2007). Characterization of side-population cells in human normal endometrium. Human Reproduction, 22(5), 1214–1223. doi:10.1093/humrep/del514.
Chan, R. W. S., & Gargett, C. E. (2006). Identification of label-retaining cells in mouse endometrium. Stem cells, 24(6), 1529–1538. doi:10.1634/stemcells.2005-0411.
Cervelló, I., Martínez-Conejero, J. A., Horcajadas, J. A., Pellicer, A., & Simón, C. (2007). Identification, characterization and co-localization of label-retaining cell population in mouse endometrium with typical undifferentiated markers. Human Reproduction (Oxford, England), 22(1), 45–51. doi:10.1093/humrep/del332.
Götte, M., Wolf, M., Staebler, A., Buchweitz, O., Kelsch, R., Schüring, A. N., & Kiesel, L. (2008). Increased expression of the adult stem cell marker Musashi-1 in endometriosis and endometrial carcinoma. The Journal of Pathology, 215(3), 317–329. doi:10.1002/path.2364.
Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews Cancer, 8(10), 755–768. doi:10.1038/nrc2499.
Allegra, A., Alonci, A., Penna, G., Innao, V., Gerace, D., Rotondo, F., & Musolino, C. (2014). The cancer stem cell hypothesis: a guide to potential molecular targets. Cancer Investigation, 32(9), 470–495. doi:10.3109/07357907.2014.958231.
Rosen, J. M., & Jordan, C. T. (2009). The increasing complexity of the cancer stem cell paradigm. Science, 324(5935), 1670–1673.
Hubbard, S. A., & Gargett, C. E. (2010). A cancer stem cell origin for human endometrial carcinoma? Reproduction, 140(1), 23–32. doi:10.1530/REP-09-0411.
Tang, D. G. (2012). Understanding cancer stem cell heterogeneity and plasticity. Cell Research, 22(3), 457–472. doi:10.1038/cr.2012.13.
Skidan, I., & Steiniger, S. (2014). Review article in vivo models for cancer stem cells research: a clinical guide. Jornal of Physiology and Pharmacology, 65(2), 157–169.
Charafe-Jauffret, E., Ginestier, C., & Birnbaum, D. (2009). Breast cancer stem cells: tools and models to rely on. BMC Cancer, 9, 202. doi:10.1186/1471-2407-9-202.
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 3983–3988. doi:10.1073/pnas.0530291100.
Morel, A. P., Lièvre, M., Thomas, C., Hinkal, G., Ansieau, S., & Puisieux, A. (2008). Generation of breast cancer stem cells through epithelial-mesenchymal transition. PloS One, 3(8), e2888. doi:10.1371/journal.pone.0002888.
Onder, T. T., Gupta, P. B., Mani, S. A., Yang, J., Lander, E. S., & Weinberg, R. A. (2008). Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Research, 68(10), 3645–3654. doi:10.1158/0008-5472.CAN-07-2938.
Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., & De Maria, R. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death and Differentiation, 15, 504–514. doi:10.1038/sj.cdd.4402283.
Zhang, W. C., Ng, S. C., Yang, H., Rai, A., Umashankar, S., Ma, S., & Lim, B. (2012). Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell, 148(1-2), 259–272. doi:10.1016/j.cell.2011.11.050.
Yamashita, T., Ji, J., Budhu, A., Forgues, M., Yang, W., Wang, Y., Wang, X. W. (2010). NIH Public Access, 136(3), 1012–1024. doi:10.1053/j.gastro.2008.12.004.EpCAM-positive.
López, J., Valdez-Morales, F. J., Benítez-Bribiesca, L., Cerbón, M., & Carrancá, A. G. (2013). Normal and cancer stem cells of the human female reproductive system. Reproductive Biology and Endocrinology : RB&E, 11(Table 2), 53. 10.1186/1477-7827-11-53
Silva, I. A., Bai, S., McLean, K., Yang, K., Griffith, K., Thomas, D., & Buckanovich, R. J. (2011). Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Research, 71(11), 3991–4001. doi:10.1158/0008-5472.CAN-10-3175.
Islam, F., Qiao, B., Smith, R. A., Gopalan, V., & Lam, A. K. Y. (2015). Cancer stem cell: Fundamental experimental pathological concepts and updates. Experimental and Molecular Pathology. doi:10.1016/j.yexmp.2015.02.002.
Gorai, I., Yanagibashi, T., Taki, A., Udagawa, K., Miyagi, E., Nakazawa, T., & Minaguchi, H. (1997). Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. International Journal of Cancer, 72(December 1996), 821–827. doi:10.1002/(SICI)1097-0215(19970904)72:5<821::AID-IJC19>3.0.CO;2-B.
Hubbard, S. A., Friel, A. M., Kumar, B., Zhang, L., Rueda, B. R., & Gargett, C. E. (2009). Evidence for cancer stem cells in human endometrial carcinoma. Cancer Research, 69(21), 8241–8248. doi:10.1158/0008-5472.CAN-08-4808.
Friel, A. M., Sergent, P. A., Patnaude, C., Szotek, P. P., Oliva, E., Scadden, D. T., & Rueda, B. R. (2008). Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells. Cell Cycle, 7(2), 242–249. doi:10.4161/cc.7.2.5207.
Kato, K., Takao, T., Kuboyama, A., Tanaka, Y., Ohgami, T., Yamaguchi, S., & Wake, N. (2010). Endometrial cancer side-population cells show prominent migration and have a potential to differentiate into the mesenchymal cell lineage. The American Journal of Pathology, 176(1), 381–392. doi:10.2353/ajpath.2010.090056.
Tomiyasu, S., Miyamoto, T., Mori, M., Yaguchi, T., Yakushiji, H., Ohno, S., & Ohno, E. (2014). Isolation of side population cells from endometrial cancer cells using a violet laser diode. Human Cell, 27, 36–42. doi:10.1007/s13577-013-0079-2.
Götte, M., Greve, B., Kelsch, R., Müller-Uthoff, H., Weiss, K., Kharabi Masouleh, B., & Buchweitz, O. (2011). The adult stem cell marker Musashi-1 modulates endometrial carcinoma cell cycle progression and apoptosis via Notch-1 and p21WAF1/CIP1. International Journal of Cancer, 129(8), 2042–2049. doi:10.1002/ijc.25856.
Zhou, X., Zhou, Y.-P., Huang, G.-R., Gong, B.-L., Yang, B., Zhang, D.-X., & Xu, S.-R. (2011). Expression of the stem cell marker, Nanog, in human endometrial adenocarcinoma. International Journal of Gynecological Pathology, 30(3), 262–270. doi:10.1097/PGP.0b013e3182055a1f.
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., & Daley, G. Q. (2008). Reprogramming of human somatic cells to pluripotency with defined factors. Nature, 451, 141–146. doi:10.1038/nature06534.
Wu, Y., Liu, S., Xin, H., Jiang, J., Younglai, E., Sun, S., & Wang, H. (2011). Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. Cancer, 117(17), 3989–3998. doi:10.1002/cncr.25944.
Honig, A., Weidler, C., Häusler, S., Krockenberger, M., Buchholz, S., Köster, F., & Engel, J. B. (2010). Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer. Anticancer Research, 30(5), 1559–1564.
Dong, P., Kaneuchi, M., Watari, H., Hamada, J., Sudo, S., Ju, J., & Sakuragi, N. (2011). MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Molecular Cancer, 10, 99. doi:10.1186/1476-4598-10-99.
Yang, M.-H., Hsu, D. S.-S., Wang, H.-W., Wang, H.-J., Lan, H.-Y., Yang, W.-H., & Wu, K.-J. (2010). Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nature Cell Biology, 12(10), 982–992. doi:10.1038/ncb2099.
Chang, S.-J., Wang, T.-Y., Tsai, C.-Y., Hu, T.-F., Chang, M. D.-T., & Wang, H.-W. (2009). Increased epithelial stem cell traits in advanced endometrial endometrioid carcinoma. BMC Genomics, 10, 613. doi:10.1186/1471-2164-10-613.
Mirantes, C., Espinosa, I., Ferrer, I., Dolcet, X., Prat, J., & Matias-Guiu, X. (2013). Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. Human Pathology, 44(10), 1973–1981. doi:10.1016/j.humpath.2013.04.009.
Cervelló, I., Mirantes, C., Santamaria, X., Dolcet, X., Matias-Guiu, X., & Simón, C. (2011). Stem cells in human endometrium and endometrial carcinoma. International Journal of Gynecological Pathology, 30(4), 317–327. doi:10.1097/PGP.0b013e3182102754.
Dong, P., Kaneuchi, M., Konno, Y., Watari, H., Sudo, S., & Sakuragi, N. (2013). Emerging therapeutic biomarkers in endometrial cancer. BioMed Research International. doi:10.1155/2013/130362.
Kusunoki, S., Kato, K., Tabu, K., Inagaki, T., Okabe, H., Kaneda, H., & Takeda, S. (2013). The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells. Gynecologic Oncology, 129, 598–605. doi:10.1016/j.ygyno.2013.03.005.
Yusuf, N., Inagaki, T., Kusunoki, S., Okabe, H., Yamada, I., Matsumoto, A., & Kato, K. (2014). SPARC was overexpressed in human endometrial cancer stem-like cells and promoted migration activity. Gynecologic Oncology, 134, 356–363. doi:10.1016/j.ygyno.2014.04.009.
Kim, J. Y., Tavaré, S., & Shibata, D. (2005). Counting human somatic cell replications: methylation mirrors endometrial stem cell divisions. Proceedings of the National Academy of Sciences of the United States of America, 102(49), 17739–17744. doi:10.1073/pnas.0503976102.
Friel, A. M., Zhang, L., Curley, M. D., Therrien, V. A., Sergent, P. A., Belden, S. E., & Rueda, B. R. (2010). Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reproductive Biology and Endocrinology, 8(1), 147. doi:10.1186/1477-7827-8-147.
Dong, P., Konno, Y., Watari, H., Hosaka, M., Noguchi, M., & Sakuragi, N. (2014). The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer. Journal of Translational Medicine, 12(1), 231. doi:10.1186/s12967-014-0231-0.
Zhou, X., Gao, Q., Wang, J., Zhang, X., Liu, K., & Duan, Z. (2014). Linc-RNA-RoR acts as a “sponge” against mediation of the differentiation of endometrial cancer stem cells by microRNA-145. Gynecologic Oncology, 133(2), 333–339. doi:10.1016/j.ygyno.2014.02.033.
Gao, Y., Liu, T., & Huang, Y. (2015). MicroRNA-134 suppresses endometrial cancer stem cells by targeting POGLUT1 and Notch pathway proteins. FEBS Letters, 589(2), 207–214. doi:10.1016/j.febslet.2014.12.002.
Konno, Y., Dong, P., Xiong, Y., Suzuki, F., & Lu, J. (2014). MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget, 5(15), 6049–6062.
Li, a, Jiao, Y., Yong, K. J., Wang, F., Gao, C., Yan, B., Chai, L. (2013). SALL4 is a new target in endometrial cancer. Oncogene, (November 2013), 1–10. doi:10.1038/onc.2013.529.
Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., & Dontu, G. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1(5), 555–567. doi:10.1016/j.stem.2007.08.014.
Rahadiani, N., Ikeda, J., Mamat, S., Matsuzaki, S., Ueda, Y., Umehara, R., & Morii, E. (2011). Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications. Cancer Science, 102(4), 903–908. doi:10.1111/j.1349-7006.2011.01864.x.
Mamat, S., Ikeda, J.-I., Tian, T., Wang, Y., Luo, W., Aozasa, K., & Morii, E. (2011). Transcriptional regulation of aldehyde dehydrogenase 1A1 gene by alternative spliced forms of nuclear factor Y in tumorigenic population of endometrial adenocarcinoma. Genes & Cancer, 2(10), 979–984. doi:10.1177/1947601911436009.
Mizrak, D., Brittan, M., & Alison, M. R. (2008). CD133: molecule of the moment. The Journal of Pathology, 214, 3–9. doi:10.1002/path.2283.
Rutella, S., Bonanno, G., Procoli, A., Mariotti, A., Corallo, M., Prisco, M. G., & Ferrandina, G. (2009). Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clinical Cancer Research, 15(13), 4299–4311. doi:10.1158/1078-0432.CCR-08-1883.
Nakamura, M., Kyo, S., Zhang, B., Zhang, X., Mizumoto, Y., Takakura, M., & Inoue, M. (2010). Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Human Pathology, 41(11), 1516–1529. doi:10.1016/j.humpath.2010.05.006.
Burke, W. M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A. B., & Shahin, F. A. (2014). Endometrial cancer: a review and current management strategies: part II. Gynecologic Oncology, 134(2), 393–402. doi:10.1016/j.ygyno.2014.06.003.
Vasiliou, V., Vasiliou, K., & Nebert, D. W. (2009). Human ATP-binding cassette (ABC) transporter family. Human Genomics, 3, 281–290. doi:10.1186/1479-7364-3-3-281.
Cojoc, M., Mäbert, K., Muders, M. H., & Dubrovska, A. (2014). A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Seminars in Cancer Biology. doi:10.1016/j.semcancer.2014.06.004.
Singh, S., Brocker, C., Koppaka, V., Chen, Y., Jackson, B. C., Matsumoto, A., & Vasiliou, V. (2013). Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radical Biology & Medicine, 56(303), 89–101. doi:10.1016/j.freeradbiomed.2012.11.010.
Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., & Brenner, M. K. (2004). A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 101(39), 14228–14233. doi:10.1073/pnas.0400067101.
Dean, M., Fojo, T., & Bates, S. (2005). Tumour stem cells and drug resistance. Nature Reviews Cancer, 5(April), 275–284. doi:10.1038/nrc1590.
Chen, L., Chang, W.-C., Hung, Y.-C., Chang, Y.-Y., Bao, B.-Y., Huang, H.-C., & Ma, W.-L. (2013). Androgen receptor increases CD133 expression and progenitor-like population that associate with cisplatin resistance in endometrial cancer cell line. Reproductive Sciences (Thousand Oaks, Calif.), 21(3), 386–394. doi:10.1177/1933719113497281.
Li, S., & Li, Q. (2014). Cancer stem cells and tumor metastasis (Review). International Journal of Oncology, 44(6), 1806–12. doi:10.3892/ijo.2014.2362.
Folkins, C., Shaked, Y., Man, S., Tang, T., Lee, C. R., Zhu, Z., & Kerbel, R. S. (2009). Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Research, 69(18), 7243–7251. doi:10.1158/0008-5472.CAN-09-0167.
Liao, W. W. W., Ye, Y. Y., Deng, Y. Y., Bian, X. X., & Ding, Y. Y. (2014). Metastatic cancer stem cells : from the concept to therapeutics. Americam Journal of Stem Cells, 3(2), 46–62.
Alonso-alconada, L., Muinelo-Romay, L., Madissoo, K., Diaz-lopez, A., Krakstad, C., Trovik, J., Romano, A. (2014). Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer, 1–10.
Dedes, K. J., Wetterskog, D., Ashworth, A., Kaye, S. B., & Reis-Filho, J. S. (2011). Emerging therapeutic targets in endometrial cancer. Nature reviewsClinical Oncology, 8(5), 261–271. doi:10.1038/nrclinonc.2010.216.
Kato, K., Kuhara, A., Yoneda, T., Inoue, T., Takao, T., Ohgami, T., & Wake, N. (2011). Sodium butyrate inhibits the self-renewal capacity of endometrial tumor side-population cells by inducing a DNA damage response. Molecular Cancer Therapeutics, 10(August), 1430–1439. doi:10.1158/1535-7163.MCT-10-1062.
Vanneman, M., & Dranoff, G. (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews Cancer. doi:10.1038/nrc3237.
Acknowledgments
The authors thank The Foundation of Science and Technology for financial support to Maria João Carvalho (SFRH/SINTD/60068/2009), Liga Portuguesa Contra o Cancro/Pfizer to Mafalda.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carvalho, M.J., Laranjo, M., Abrantes, A.M. et al. Clinical translation for endometrial cancer stem cells hypothesis. Cancer Metastasis Rev 34, 401–416 (2015). https://doi.org/10.1007/s10555-015-9574-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-015-9574-0